Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650421 | 0.94 | MEN1 (0.32) | ELANEMEN1RAB9AKMT2AATM | |
| SCHEMBL649824 | 0.88 | MEN1 (0.33) | ELANEMEN1RAB9AKMT2AATM | |
| SCHEMBL650877 | 0.87 | ELANE (0.33) | ELANENQO1CYP1A2CYP2A6TLR8 | |
| SCHEMBL650993 | 0.86 | ELANE (0.35) | ELANEMEN1RAB9AKMT2AATM | |
| SCHEMBL650014 | 0.83 | ATM (0.33) | MEN1RAB9AKMT2AATMALDH1A1 | |
| SCHEMBL650640 | 0.82 | NQO1 (0.31) | ELANENQO1CYP1A2CYP2A6TLR8 | |
| SCHEMBL650542 | 0.81 | ELANE (0.31) | ELANEALDH1A1 | |
| SCHEMBL652152 | 0.81 | ELANE (0.32) | ELANEMEN1RAB9AKMT2AATM | |
| SCHEMBL648822 | 0.79 | ELANE (0.35) | ELANERAB9ANQO1CYP1A2CYP2A6 | |
| SCHEMBL652147 | 0.78 | ELANE (0.41) | ELANEMEN1RAB9AKMT2ANQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119667-B2 | Carbonates of fenicol antibiotics | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2012-02-21 | — | — | US | claimed |
| US-7842942-B2 | Organic semiconducting layers | MERCK PATENT GMBH (DE) | 2010-11-30 | — | — | US | claimed |
| US-8119804-B2 | Organic semiconducting layers | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-7842942-B2 | Organic semiconducting layers | MERCK PATENT GMBH (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7807993-B2 | Organic pentacene semiconducting layers | MERCK PATENT GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20100227956-A1 | Organic Semiconducting Layers | FLEXENABLE TECHNOLOGY LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-1687830-B1 | ORGANIC SEMICONDUCTING LAYER FORMULATIONS COMPRISING POLYACENES AND ORGANIC BINDER POLYMERS | MERCK PATENT GMBH (DE) | 2010-07-28 | — | — | EP | disclosed |
| US-7576208-B2 | Organic semiconductor layers | MERCK PATENT GMBH (DE) | 2009-08-18 | — | — | US | disclosed |
| EP-1808866-A1 | Organic semiconducting layer formulations comprising polyacenes and organic binder polymers | Merck Patent GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070137520-A1 | ORGANIC SEMICONDUCTING LAYERS | FLEXENABLE TECHNOLOGY LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070102696-A1 | Organic semiconducting layers | FLEXENABLE TECHNOLOGY LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1783781-A2 | ORGANIC SEMICONDUCTING LAYER FORMULATIONS COMPRISING POLYACENES AND ORGANIC BINDER POLYMERS | Merck Patent GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1687830-A2 | ORGANIC SEMICONDUCTING LAYER FORMULATIONS COMPRISING POLYACENES AND ORGANIC BINDER POLYMERS | Merck Patent GmbH (DE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005055248-A2 | ORGANIC SEMICONDUCTING LAYER FORMULATIONS COMPRISING POLYACENES AND ORGANIC BINDER POLYMERS | MERCK PATENT GMBH (DE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070102696-A1 | Organic semiconducting layers | SSB, RCOR3, CNKSR1 | ELANE 1532/4885MEN1 3671/4885RAB9A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.